Lebrikizumab
- Generic Name
- Lebrikizumab
- Brand Names
- Ebglyss
- Drug Type
- Biotech
- CAS Number
- 953400-68-5
- Unique Ingredient Identifier
- U9JLP7V031
- Background
Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
- First Posted Date
- 2013-06-03
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1081
- Registration Number
- NCT01867125
- Locations
- 🇺🇸
Choc Psf, Amc, Orange, California, United States
🇺🇸North Bay Clinical Trials, Napa, California, United States
🇺🇸Bensch Research Associates, Stockton, California, United States
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT01545440
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT01545453
A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01423318
A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT00971035
A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT00930163
A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00781443
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
Phase 1
- Conditions
- Hodgkin's Lymphoma
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Tanox
- Target Recruit Count
- 59
- Registration Number
- NCT00441818
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center - Dept. of Lymphoma and Myeloma, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath